Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is a promising telehealth company with a strong track record of revenue growth and strategic partnerships in the healthcare industry. While there are concerns about profitability and potential legal risks, the company's focus on long-term growth and expansion into international markets bodes well for its future success. However, maintaining profitability and overcoming challenges in personalization and customer retention will be key areas to monitor for investors.

Bears say

Hims & Hers Health is facing several risks that may hinder its long-term growth potential and profitability. These risks include fierce competition, tighter regulatory scrutiny and changes, and the potential impact of a strategic partnership with Novo Nordisk on its business model. The company's recent partnership with Novo Nordisk may provide a near-term boost in revenue, but there are concerns about the viability of its compounded medication offerings and the potential for increased costs and customer attrition in the long run. Overall, the company's current financials and outlook suggest that it may struggle to maintain a competitive edge and achieve long-term profitability.

HIMS has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Buy based on their latest research and market trends.

According to 13 analysts, HIMS has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.